Structures by: Florence A. J.
Total: 219
Carbamazepine trifluoroacetic acid solvate
C15H12N2O,C2HF3O2
Acta Crystallographica Section E (2007) 63, 11 o4269-o4269
a=15.0142(4)Å b=5.28710(10)Å c=20.2489(6)Å
α=90.00° β=101.735(3)° γ=90.00°
Urea DMF solvate (3/1)
C3H7NO,3(CH4N2O)
Acta Crystallographica Section E (2007) 63, 12 o4861-o4861
a=7.5246(13)Å b=9.866(4)Å c=10.821(4)Å
α=65.61(4)° β=79.43(2)° γ=70.76(2)°
Chlorothiazide--pyridine (1/3)
C7H6ClN3O4S2,3(C5H5N)
Acta Crystallographica Section E (2008) 64, 6 o1105-o1106
a=9.0697(15)Å b=11.863(2)Å c=11.875(2)Å
α=100.691(7)° β=98.667(8)° γ=98.134(7)°
Cytenamide acetic acid solvate
C16H13NO,C2H4O2
Acta Crystallographica Section E (2008) 64, 6 o1175-o1176
a=5.8726(17)Å b=14.418(3)Å c=18.182(4)Å
α=90° β=95.13(2)° γ=90°
Dihydrocarbamazepine formamide
C15H14N2O,CH3NO
Acta Crystallographica Section E (2007) 63, 9 o3888-o3889
a=8.4690(4)Å b=9.0215(4)Å c=10.3137(4)Å
α=74.363(3)° β=83.630(3)° γ=70.847(3)°
10,11-Dihydrocarbamazepine--dimethyl sulfoxide (1/1)
C15H14N2O1,C2H6OS
Acta Crystallographica Section E (2007) 63, 9 o3918-o3919
a=10.2696(3)Å b=6.8543(2)Å c=23.3599(6)Å
α=90.00° β=98.932(2)° γ=90.00°
Dihydrocarbamazepine Form III
C15H14N2O1
Acta Crystallographica Section E (2007) 63, 2 o675-o677
a=5.4233(12)Å b=9.200(5)Å c=24.189(6)Å
α=87.59(3)° β=84.23(2)° γ=88.93(3)°
10,11-Dihydrocarbamazepine--formic acid (1/1)
C15H14N2O,CH2O2
Acta Crystallographica Section E (2007) 63, 3 o1469-o1470
a=5.2298(4)Å b=9.3849(12)Å c=14.4858(18)Å
α=83.853(5)° β=88.230(7)° γ=88.221(7)°
Chlorothiazide formic acid solvate (1/2)
C7H6ClN3O4S2,2(CH2O2)
Acta Crystallographica Section E (2007) 63, 10 o4021-o4021
a=8.2985(5)Å b=21.5271(14)Å c=8.3676(5)Å
α=90.00° β=105.580(3)° γ=90.00°
Hydroflumethiazide dimethylsulfoxide disolvate
C8H8F3N3O4S2,2C2H6OS
Acta Crystallographica Section E (2007) 63, 10 o3956-o3956
a=5.55700(10)Å b=20.8433(4)Å c=17.4142(3)Å
α=90.00° β=93.540(2)° γ=90.00°
Urea--dimethylacetamide
C4H9NO,CH4N2O
Acta Crystallographica Section E (2008) 64, 2 o355-o355
a=7.2770(3)Å b=17.5394(9)Å c=7.3789(4)Å
α=90° β=119.450(3)° γ=90°
Cytenamide--butyric acid (1/1)
C16H13NO,C4H8O2
Acta Crystallographica Section E (2008) 64, 7 o1295-o1296
a=5.9351(2)Å b=16.3595(5)Å c=17.6738(4)Å
α=90° β=98.046(2)° γ=90°
Cytenamide trifluoroacetic acid solvate
C16H13NO,C2HF3O2
Acta Crystallographica Section E (2008) 64, 7 o1215-o1216
a=12.1673(11)Å b=6.3235(6)Å c=21.4525(15)Å
α=90° β=101.932(8)° γ=90°
Cytenamide--1,4-dioxane (2/1)
2C16H13NO,C4H8O2
Acta Crystallographica Section E (2008) 64, 7 o1345-o1346
a=24.0888(7)Å b=5.6066(2)Å c=21.1050(6)Å
α=90° β=90.313(3)° γ=90°
10,11-Dihydrocarbamazepine--acetic acid (1/1)
C15H14N2O,C2H4O2
Acta Crystallographica Section E (2006) 62, 12 o5361-o5362
a=5.3104(4)Å b=15.4246(17)Å c=18.732(2)Å
α=90.00° β=95.106(7)° γ=90.00°
Cyheptamide
C16H15NO
Acta Crystallographica Section E (2007) 63, 1 o205-o206
a=5.6035(7)Å b=9.1716(11)Å c=23.579(3)Å
α=90.00° β=96.752(12)° γ=90.00°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o202-o204
a=11.88215(15)Å b=5.97647(8)Å c=13.07499(15)Å
α=90° β=113.5100(10)° γ=90°
Chlorothiazide DMSO solvate
C7H6ClN3O4S2,C2H6OS
Acta Crystallographica Section E (2007) 63, 5 o2423-o2423
a=9.0965(3)Å b=11.2081(4)Å c=15.8916(5)Å
α=109.009(2)° β=103.384(2)° γ=96.246(2)°
Chlorothiazide N,N-dimethylacetamide solvate
C7H6ClN3O4S2,2C4H9NO
Acta Crystallographica Section E (2007) 63, 5 o2422-o2422
a=8.2037(3)Å b=24.5226(6)Å c=10.6443(3)Å
α=90.00° β=105.231(2)° γ=90.00°
Cytenamide--formic acid (1/1)
C16H13NO,CH2O2
Acta Crystallographica Section E (2008) 64, 8 o1379-o1380
a=11.5351(13)Å b=13.9095(15)Å c=17.6904(19)Å
α=90.00° β=95.846(5)° γ=90.00°
Ciprofloxacin--2,2-difluoroethanol (2/3)
2(C17H18FN3O3),3(C2H4F2O)
Acta Crystallographica Section C (2011) 67, 3 o120-o124
a=10.9848(4)Å b=13.9800(4)Å c=13.9802(4)Å
α=105.6488(18)° β=90.352(2)° γ=93.364(2)°
Ciprofloxacin--water (3/14.5)
3(C17H18FN3O3),14.5(H2O)
Acta Crystallographica Section C (2011) 67, 3 o120-o124
a=13.8760(12)Å b=15.8760(13)Å c=16.528(2)Å
α=115.755(7)° β=103.610(7)° γ=102.325(5)°
Bendroflumethiazide acetone solvate
C15H14F3N3O4S2,C3H6O
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.192(2)Å b=9.525(2)Å c=14.101(2)Å
α=99.538(17)° β=100.171(17)° γ=100.42(2)°
Bendroflumethiazide N,N-dimethylformamide solvate
C15H14F3N3O4S2,C3H7NO
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.2527(3)Å b=17.8431(7)Å c=14.9012(5)Å
α=90° β=103.752(4)° γ=90°
Loxapine succinate monohydrate
2(C18H19ClN3O),C4H4O42,C4H6O4,2(H2O)
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=9.4171(6)Å b=9.7604(7)Å c=13.7949(9)Å
α=74.708(2)° β=86.102(2)° γ=65.518(2)°
Loxapine succinate
C18H19ClN3O,C4H5O4
Acta Crystallographica Section C (2013) 69, 11 1273-1278
a=36.1824(5)Å b=7.08622(14)Å c=18.7690(2)Å
α=90° β=113.8402(10)° γ=90°
Norfloxacin dihydrate
C16H18FN3O3,2H2O
Acta Crystallographica Section C (2000) 56, 11 1372-1373
a=8.265(3)Å b=21.698(4)Å c=9.5250(17)Å
α=90.00° β=110.794(19)° γ=90.00°
3-Aminocarbonylpyridinium difluoroacetate
C6H7N2O,C2HF2O2
Acta Crystallographica Section E (2009) 65, 11 o2896-o2897
a=4.9888(2)Å b=25.6147(12)Å c=7.2006(4)Å
α=90° β=105.912(2)° γ=90°
Nicotinamide 2,2,2-trifluoroethanol(2/1)
2(C6H6N2O),C2H3F3O
Acta Crystallographica Section E (2009) 65, 4 o727-o728
a=5.0472(3)Å b=11.2930(7)Å c=15.0877(10)Å
α=107.002(3)° β=96.636(3)° γ=95.753(3)°
6-Methyl-1,3,5-triazine-2,4-diamine butane-1,4-diol monosolvate
C4H7N5,C4H10O2
Acta Crystallographica Section E (2012) 68, 12 o3377
a=5.8755(3)Å b=9.0515(5)Å c=10.7607(5)Å
α=87.911(3)° β=74.346(3)° γ=83.550(3)°
Olanzapine propan-2-ol disolvate
C17H20N4S,2(C3H8O)
Acta Crystallographica Section E (2013) 69, 5 o752-o753
a=9.9621(5)Å b=10.8702(6)Å c=12.2298(7)Å
α=70.421(2)° β=74.560(2)° γ=77.296(2)°
C48H66N4O5
C48H66N4O5
Crystal Growth & Design (2014) 14, 5 2422
a=9.8166(15)Å b=15.448(3)Å c=17.313(3)Å
α=114.971(7)° β=100.174(9)° γ=90.326(9)°
C48H66N4O5
C48H66N4O5
Crystal Growth & Design (2014) 14, 5 2422
a=9.8183(4)Å b=15.4270(6)Å c=46.7832(17)Å
α=81.262(3)° β=88.059(3)° γ=89.925(3)°
2(C5H5ClN),Cl4Cu
2(C5H5ClN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.1853(3)Å b=7.6605(3)Å c=15.4482(6)Å
α=82.336(3)° β=80.555(3)° γ=70.735(3)°
2(C5H5ClN),Cl4Cu
2(C5H5ClN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.3119(4)Å b=7.7799(4)Å c=15.4970(8)Å
α=81.684(3)° β=79.779(3)° γ=69.368(3)°
Bis(3-chloropyridine)copper(II) chloride
C10H8Cl4CuN2
Journal of the American Chemical Society (2006) 128, 9584-9585
a=3.813149(51)Å b=13.70256(16)Å c=12.11849(19)Å
α=90° β=92.3372(11)° γ=90°
2(C5H5BrN),Cl4Cu
2(C5H5BrN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.5702(5)Å b=7.8282(6)Å c=15.5620(11)Å
α=82.064(4)° β=78.890(4)° γ=67.093(4)°
2(C5H5BrN),Cl4Cu
2(C5H5BrN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.407(4)Å b=7.703(4)Å c=15.506(8)Å
α=82.644(10)° β=79.837(10)° γ=68.888(9)°
2(C5H5BrN),Cl4Cu
2(C5H5BrN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.56821(22)Å b=7.82283(22)Å c=15.55510(44)Å
α=82.1012(15)° β=78.9087(17)° γ=67.0878(15)°
Bis(3-bromopyridine)copper(II) chloride
C10H8Br2Cl2CuN2
Journal of the American Chemical Society (2006) 128, 9584-9585
a=3.88094(28)Å b=13.83710(92)Å c=12.16111(84)Å
α=90° β=91.4741(21)° γ=90°
2(C5H5ClN),Cl4Cu
2(C5H5ClN),Cl4Cu
Journal of the American Chemical Society (2006) 128, 9584-9585
a=7.30931(17)Å b=7.77643(18)Å c=15.49792(37)Å
α=81.6898(14)° β=79.7745(16)° γ=69.3487(15)°
1-nitro-2,4-Dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=20.682(3)Å b=3.7484(5)Å c=20.961(3)Å
α=90.00° β=118.235(2)° γ=90.00°
1-nitro-2,5-dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=7.1403(8)Å b=7.2638(8)Å c=8.2418(9)Å
α=72.781(2)° β=70.300(2)° γ=66.349(2)°
1-Chloro-3,4-dinitrobenzene beta polymorph
C6H3ClN2O4
Crystal Growth & Design (2008) 8, 1 24
a=7.554(3)Å b=7.821(3)Å c=13.453(5)Å
α=90.00° β=96.307(7)° γ=90.00°
1-nitro-3,4-dichlorobenzene
C6H3Cl2NO2
Crystal Growth & Design (2008) 8, 1 24
a=27.9342(19)Å b=27.9342(19)Å c=3.7655(5)Å
α=90.00° β=90.00° γ=90.00°
1-Chloro-3,4-dinitrobenzene gamma polymorph
C6H3ClN2O4
Crystal Growth & Design (2008) 8, 1 24
a=5.5245(11)Å b=11.778(2)Å c=11.939(2)Å
α=90.00° β=90.00° γ=90.00°
Naproxen
C14H14O3
Crystal Growth & Design (2011) 11, 12 5659
a=25.8301(13)Å b=15.4939(4)Å c=5.9465(2)Å
α=90° β=90° γ=90°
Beta resoryclic acid form I
C7H6O4
Crystal growth & design (2011) 11, 1 210-220
a=23.1978(4)Å b=5.5469(1)Å c=5.1980(1)Å
α=90° β=92.215(1)° γ=90°
Beta resoryclic acid hemihydrate
2(C7H6O4),H2O
Crystal growth & design (2011) 11, 1 210-220
a=7.0270(4)Å b=9.5449(4)Å c=11.1763(5)Å
α=96.684(4)° β=104.319(5)° γ=98.903(4)°
Beta resoryclic DMSO hemisolvate
2(C7H6O4),C2H6OS
Crystal growth & design (2011) 11, 1 210-220
a=6.39832(12)Å b=11.7099(3)Å c=23.2362(5)Å
α=90° β=90° γ=90°
Beta resoryclate pyridinium salt
C7H5O4,C5H6N
Crystal growth & design (2011) 11, 1 210-220
a=11.7363(4)Å b=8.5691(2)Å c=11.8310(4)Å
α=90° β=115.973(5)° γ=90°
C14H18MgO8
C14H18MgO8
Crystal Growth & Design (2011) 11, 4 1318
a=8.8802(16)Å b=10.4210(18)Å c=35.019(6)Å
α=90.00° β=97.228(3)° γ=90.00°
C14H12O5Sr
C14H12O5Sr
Crystal Growth & Design (2011) 11, 4 1318
a=11.8003(4)Å b=7.1674(2)Å c=15.7364(5)Å
α=90.00° β=99.998(2)° γ=90.00°
C14H12F2MgO6
C14H12F2MgO6
Crystal Growth & Design (2011) 11, 4 1318
a=7.2810(5)Å b=6.6002(4)Å c=14.6587(9)Å
α=90.00° β=99.973(3)° γ=90.00°
C14H14BaO6
C14H14BaO6
Crystal Growth & Design (2011) 11, 4 1318
a=7.5980(3)Å b=12.9258(5)Å c=30.7127(14)Å
α=90.00° β=94.956(2)° γ=90.00°
C14H17.48F2O8.74Sr
C14H17.48F2O8.74Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.7231(3)Å b=7.4076(3)Å c=16.6220(10)Å
α=82.951(4)° β=89.380(4)° γ=84.302(4)°
C14H8BaF2O4
C14H8BaF2O4
Crystal Growth & Design (2011) 11, 4 1318
a=10.3942(5)Å b=7.7929(5)Å c=16.1632(10)Å
α=90.00° β=103.679(4)° γ=90.00°
C14H16Cl2MgO8
C14H16Cl2MgO8
Crystal Growth & Design (2011) 11, 4 1318
a=39.8060(18)Å b=10.3870(5)Å c=8.8480(4)Å
α=90.00° β=91.039(2)° γ=90.00°
C14H14CaCl2O7
C14H14CaCl2O7
Crystal Growth & Design (2011) 11, 4 1318
a=6.5797(9)Å b=34.867(5)Å c=7.1797(11)Å
α=90.00° β=93.184(5)° γ=90.00°
C14H16Cl2O8Sr
C14H16Cl2O8Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.7800(2)Å b=7.5071(2)Å c=17.5087(5)Å
α=81.9304(14)° β=89.7850(15)° γ=83.9229(16)°
C14H16BaCl2O8
C14H16BaCl2O8
Crystal Growth & Design (2011) 11, 4 1318
a=7.0487(5)Å b=7.6124(5)Å c=17.3085(14)Å
α=80.425(6)° β=89.215(6)° γ=82.281(6)°
C14H16CaN2O6
C14H16CaN2O6
Crystal Growth & Design (2011) 11, 4 1318
a=6.607(2)Å b=13.075(3)Å c=18.444(4)Å
α=90.00° β=90.00° γ=90.00°
C14H24MgN2O16
C14H24MgN2O16
Crystal Growth & Design (2011) 11, 4 1318
a=13.8735(6)Å b=14.1004(5)Å c=14.0354(6)Å
α=86.534(2)° β=62.119(2)° γ=62.583(2)°
C14H26CaN2O17
C14H26CaN2O17
Crystal Growth & Design (2011) 11, 4 1318
a=15.093(2)Å b=9.9490(5)Å c=15.713(2)Å
α=90.00° β=94.767(2)° γ=90.00°
C14H26N2O17Sr
C14H26N2O17Sr
Crystal Growth & Design (2011) 11, 4 1318
a=6.6527(6)Å b=11.1343(10)Å c=31.494(3)Å
α=90.00° β=94.882(4)° γ=90.00°
C14H18BaN2O13
C14H18BaN2O13
Crystal Growth & Design (2011) 11, 4 1318
a=6.5280(2)Å b=10.6570(3)Å c=28.3021(5)Å
α=90.00° β=91.1560(10)° γ=90.00°
C14H16MgN2O12
C14H16MgN2O12
Crystal Growth & Design (2011) 11, 4 1318
a=5.2497(5)Å b=7.6168(8)Å c=11.7111(13)Å
α=81.763(4)° β=78.428(5)° γ=73.836(5)°
C14H12BaO7
C14H12BaO7
Crystal Growth & Design (2011) 11, 4 1318
a=9.2329(2)Å b=10.0390(3)Å c=15.6860(5)Å
α=101.0560(10)° β=98.483(2)° γ=99.498(2)°
C14H16N2O12Sr
C14H16N2O12Sr
Crystal Growth & Design (2011) 11, 4 1318
a=4.0818(3)Å b=31.856(2)Å c=6.800(4)Å
α=90.00° β=94.378(3)° γ=90.00°
C14H12CaN2O10
C14H12CaN2O10
Crystal Growth & Design (2011) 11, 4 1318
a=7.7232(2)Å b=10.1673(3)Å c=11.1947(3)Å
α=81.3530(10)° β=82.231(2)° γ=89.441(2)°
C14H14BaN2O11
C14H14BaN2O11
Crystal Growth & Design (2011) 11, 4 1318
a=8.2858(2)Å b=8.3482(1)Å c=13.8501(3)Å
α=80.492(1)° β=85.986(1)° γ=71.065(1)°
C14H18BaN2O9
C14H18BaN2O9
Crystal Growth & Design (2011) 11, 4 1318
a=13.0200(4)Å b=4.3220(1)Å c=15.3326(5)Å
α=90.00° β=104.740(1)° γ=90.00°
C14H16.9BaN2O6.45
C14H16.9BaN2O6.45
Crystal Growth & Design (2011) 11, 4 1318
a=33.755(2)Å b=12.908(2)Å c=7.542(2)Å
α=90.00° β=96.02(2)° γ=90.00°
C14H13CaN2O6.5
C14H13CaN2O6.5
Crystal Growth & Design (2011) 11, 4 1318
a=14.9499(6)Å b=8.8062(4)Å c=22.3285(9)Å
α=90.00° β=104.359(3)° γ=90.00°
C14H13N2O6.5Sr
C14H13N2O6.5Sr
Crystal Growth & Design (2011) 11, 4 1318
a=15.146(1)Å b=9.0220(6)Å c=22.492(1)Å
α=90.00° β=105.794(1)° γ=90.00°
Remacemide
C17H20N2O
Crystal Growth & Design (2005) 5, 2 427
a=8.9200(10)Å b=16.524(2)Å c=9.8570(10)Å
α=90.00° β=93.836(10)° γ=90.00°
Remacemide nitrate
C17H21N2O1,N1O3
Crystal Growth & Design (2005) 5, 2 427
a=11.724(4)Å b=8.932(4)Å c=15.872(4)Å
α=90.00° β=95.93(2)° γ=90.00°
Remacemide xinafoate
C17H21N2O1,C11H7O3
Crystal Growth & Design (2005) 5, 2 427
a=11.9187(10)Å b=31.801(3)Å c=7.9304(7)Å
α=90.00° β=128.382(2)° γ=90.00°
Remacemide acetate
C17H21N2O1,C2H3O2
Crystal Growth & Design (2005) 5, 2 427
a=15.4018(3)Å b=6.7683(1)Å c=17.3531(3)Å
α=90.0° β=93.13(1)° γ=90.0°
Remacemide napsilate
C17H21N2O1,C10H7SO3,0.4(C2H6O1),0.5(H2O1)
Crystal Growth & Design (2005) 5, 2 427
a=9.7297(4)Å b=14.4323(3)Å c=19.4269(4)Å
α=104.859(2)° β=90.490(2)° γ=95.546(2)°
3,4,5-trihydroxybenzoic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=25.685(3)Å b=4.9273(5)Å c=11.2508(12)Å
α=90° β=106.234(2)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=5.2303(1)Å b=5.26495(12)Å c=24.7927(4)Å
α=90° β=102.1116(17)° γ=90°
Gallic acid
C7H6O5,H2O
Crystal growth & design (2013) 13, 1 19-23
a=7.60719(9)Å b=3.64133(4)Å c=26.7915(4)Å
α=90° β=98.4212(11)° γ=90°
Gallic acid
C7H6O5
Crystal growth & design (2013) 13, 1 19-23
a=7.31853(19)Å b=8.2536(2)Å c=11.7148(3)Å
α=100.4719(12)° β=90.2335(17)° γ=90.9844(17)°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3411(13)Å b=14.521(2)Å c=10.5314(14)Å
α=90.00° β=100.291(4)° γ=90.00°
Olanzapine
C17H20N4S1
Crystal Growth & Design (2013) 13, 4 1602
a=9.8544(14)Å b=16.314(2)Å c=9.9754(12)Å
α=90.00° β=98.304(8)° γ=90.00°
Olanzapine 2-butoxyethanol
C17H20N4S1,(C6H14O2)
Crystal Growth & Design (2013) 13, 4 1602
a=10.4420(10)Å b=17.7328(15)Å c=15.5165(13)Å
α=90.00° β=126.279(5)° γ=90.00°
Olanzapine 2,2,2-trifluoroethanol
C17H20N4S1,2(C2F3O1H3)
Crystal Growth & Design (2013) 13, 4 1602
a=12.7244(9)Å b=11.7538(8)Å c=16.0067(11)Å
α=90.00° β=94.782(2)° γ=90.00°
Olanzapine acetic acid
C17H20N4S1(C2O2H4)
Crystal Growth & Design (2013) 13, 4 1602
a=10.0427(11)Å b=12.7430(13)Å c=14.3886(15)Å
α=90.00° β=92.436(4)° γ=90.00°
Olanzapine ethyleneglycol
C17H20N4S1,(C2H6O2)
Crystal Growth & Design (2013) 13, 4 1602
a=9.8393(16)Å b=13.278(2)Å c=14.588(2)Å
α=90.00° β=96.328(7)° γ=90.00°
Olanzapine ethanol
C17H20N4S1,C2H6O1
Crystal Growth & Design (2013) 13, 4 1602
a=10.3489(18)Å b=13.003(2)Å c=13.870(2)Å
α=90.00° β=92.496(6)° γ=90.00°
Olanzapine TBMe hydrate
C17H20N4S1,(C5H12O1),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2070(1)Å b=12.2211(9)Å c=14.550(1)Å
α=90.00° β=109.239(3)° γ=90.00°
Olanzapine t-butanol hydrate
2(C17H20N4S1),2(C4H10O1),5(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.2491(9)Å b=12.3838(8)Å c=27.1418(17)Å
α=90.00° β=99.052(2)° γ=90.00°
Olanzapine 3-methyl 1-butanol hydrate
2(C17H20N4S1),2(C5H12O1),2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=12.3420(17)Å b=13.3559(18)Å c=14.630(2)Å
α=105.883(6)° β=90.290(6)° γ=92.005(6)°
Olanzapine N,N dimethylforamide hydrate
2(C17H20N4S),(C3H7NO1)2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=14.9885(9)Å b=12.7558(7)Å c=19.8567(12)Å
α=90.00° β=93.348(2)° γ=90.00°
Olanzapine 1.4-butanediol hydrate
2(C17H20N4S1),(C4O2H10),2(H2O1)
Crystal Growth & Design (2013) 13, 4 1602
a=12.2637(11)Å b=14.1146(10)Å c=14.1783(12)Å
α=63.985(3)° β=65.649(4)° γ=65.437(4)°
Olanzapine-2-pentanol hydrate
C17H20N4S1,C5H12O1,H2O
Crystal Growth & Design (2013) 13, 4 1602
a=13.4466(10)Å b=12.3833(9)Å c=14.5522(9)Å
α=90.00° β=104.839(2)° γ=90.00°
Olanzapine N,N,N-triethylamine hydrate
(C17H20N4S),0.5(C6H15N)2(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=14.8170(10)Å b=12.6230(10)Å c=14.4610(10)Å
α=90.00° β=113.36(2)° γ=90.00°
Olanzapine 1-butanol hydrate
C17H20N4S1,0.5(C4H10O1),H2O1
Crystal Growth & Design (2013) 13, 4 1602
a=24.575(6)Å b=12.429(3)Å c=15.006(3)Å
α=90.00° β=125.255(7)° γ=90.00°
Olanzapine nitromethane hydrate
C17H20N4S1,0.5(CH3NO2),(H2O)
Crystal Growth & Design (2013) 13, 4 1602
a=24.352(3)Å b=12.3706(13)Å c=15.0182(18)Å
α=90.00° β=125.531(5)° γ=90.00°